sotrovimab 
GtoPdb Ligand ID: 11333
|
Synonyms: GSK-4182136 | GSK4182136 | VIR-7831 | VIR7831 | Xevudy®
sotrovimab is an approved drug (UK & EMA (2021))
Compound class:
Antibody
Comment: Sotrovimab (VIR-7831) is a monoclonal antibody that binds to a highly conserved epitope within the surface spike glycoprotein of sarbecoviruses. The parental antibody, from which sotrovimab was derived, was originally identified in the memory B cells of a patient who had recovered from SARS-CoV infection. Sotrovimab was progressed by GSK and Vir Biotechnology as a COVID-19 therapeutic [4]. Sotrovimab retains some activity against the omicron BA.1 (B.1.1.529) SARS-CoV-2 variant (bioRxiv preprint [1]), but it activity against the BA.2 omicron subvariant is lower [3].
|
| Bioactivity Comments |
| In vitro, sotrovimab induces both antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP) [2]. |
| Selectivity at other protein targets | ||||||||||||||||||||||||||||||||||
| Key to terms and symbols | Click column headers to sort | |||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License